Figure 2.
Survival curves regarding PSMA+ CTCs (A,B) and AR-V7+ CTCs (C,B) in primary TNBC patients before neoadjuvant treatment. Survival intervals were screened from the time of first diagnosis until the date of recurrence [here disease-free survival; (A,C)] or death [overall survival; (B,D)] and calculated with Kaplan-Meier estimator (Log-rank test).